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a b s t r a c t
As polyphenolic compounds isolated from plants extracts, ﬂavonoids have been applied to various phar-
maceutical uses in recent decades due to their anti-inﬂammatory, cancer preventive, and cardiovascular
protective activities. In this study, we evaluated the effects of the ﬂavonoid quercetin on Crotalus durissus
terriﬁcus secretory phospholipase A2 (sPLA2), an important protein involved in the release of arachidonic
acid from phospholipid membranes. The protein was chemically modiﬁed by treatment with quercetin,
which resulted in modiﬁcations in the secondary structure as evidenced through circular dichroism. In
addition, quercetin was able to inhibit the enzymatic activity and some pharmacological activities of
sPLA2, including its antibacterial activity, its ability to induce platelet aggregation, and its myotoxicityuercetin
harmacological sites
olecular docking
by approximately 40%, but was not able to reduce the inﬂammatory and neurotoxic activities of sPLA2.
These results suggest the existence of two pharmacological sites in the protein, one that is correlated
with the enzymatic site and another that is distinct from it. We also performed molecular docking to
better understand the possible interactions between quercetin and sPLA2. Our docking data showed the
existence of hydrogen-bonded, polar interactions and hydrophobic interactions, suggesting that other
tructu
s as sﬂavonoids with similar s
potential use of ﬂavonoid
. Introduction
Phospholipases A2 (PLA2, EC 3.1.1.4) are small proteins that
atalyze the hydrolysis of glycerophospholipids at the sn-2 posi-
ion in a Ca2+-dependent reaction, releasing lysophospholipids and
atty acids [1–3]. These enzymes are the main component of snake
enom and have been investigated not only because they have
wide range of biological effects, but also due to their similar-
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Open access under the Elsevier OA license.res could bind to sPLA2. Further research is warranted to investigate the
PLA2 inhibitors.
© 2010 Elsevier Ireland Ltd. 
ity to mammalian phospholipases [4,5]. However, in contrast to
theirmammalian counterparts, several snakevenomPLA2s are tox-
ins that induce pharmacological effects [6] through arachidonic
acid metabolism leading to the production of various lipid pro-
inﬂammatory mediators such as prostaglandins, thromboxanes
and leukotrienes [7]. Recent studies have shown that inhibition of
cytosolic PLA2 (cPLA2) leads to a decrease in eicosanoid levels and,
reduced inﬂammation [8].
Due to the role of PLA2s in the inﬂammatory process, there is
pharmacological interest in PLA2 inhibitors, and among these, the
ﬂavonoids have been successfully studied. Flavonoids are widely
produced in plants tissues making them suitable targets for phar-
maceutical extraction and chemical synthesis [8,9]. The inhibitory
effect of ﬂavonoids on secretory PLA2 (sPLA2) was reported by Gil
Open access under the Elsevier OA license.et al. [10], and Lindahl and Tagesson [11]. Their results showed
that inhibition of sPLA2 from different sources following incu-
bation with various ﬂavonoids is dependent on the 5-hydroxyl
group as well as the double bond and the double-bonded oxygen
in the oxane ring, and that the hydroxyl groups at the 3′- and 4′-
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osition are required for selective inhibition of PLA2 [11]. However,
he exact mechanism by which ﬂavonoids inhibit PLA2 remains
nclear. Iglesias et al. [12] showed that morin modiﬁes the sec-
ndary structure of sPLA2 from Crotalus durissus cascavella venom,
ut did not signiﬁcantly affect its pharmacological activities.
Although there are studies of ﬂavonoids as PLA2 inhibitors, the
ode of binding of ﬂavonoids to PLA2 as well as their inhibitory
echanism is still not clear. The aims of this article are to inves-
igate the effect of quercetin, a widely spread ﬂavonoid, on the
tructure and function of a sPLA2 isolated from Crotalus duris-
us terriﬁcus, to increase our understanding of the mode action
f polyphenolic compounds on the snake venoms, and to evalu-
te therapeutic application against the symptoms caused by snake
ites. In the last decades the action of quercetin on the PLA2 has
een studied. In 1993 Lindahl and Tagesson [13] showed that
uercetin is a potent inhibitor of PLA2 (group II) from Vipera russuli.
n addition, Lättig et al. [8] showed through computational stud-
es chemical interactions between humans’ sPLA2 and quercetin.
ue to these characteristics, quercetinhas been chosen asﬂavonoid
odel. Moreover we also propose, through high-resolution three-
imensional (3D) data (molecular docking), a structural model
or understanding the molecular interactions between sPLA2 and
uercetin, andhow it can inﬂuence enzymatic andpharmacological
ctivities of sPLA2.
. Materials and methods
.1. Venom, animals and reagents
C. durissus terriﬁcus venom was purchased from Bio-Agents
erpentarium (Batatais, São Paulo, Brazil). Analytical HPLC- and
equencing-grade solutes and solvents were purchased from vari-
us suppliers (Bio Rad, Sigma Aldrich, Boehringer Mannheim, and
pplied Biosystems). Female Swiss mice (18–20g) used in the
harmacological assays were obtained from the Multidisciplinary
enter of Biological Investigations (CEMIB-UNICAMP) and male
hicks were obtained from Itu farm in Campinas City. All animal
xperiments were approved by the Ethics Committee of State Uni-
ersity of Campinas (São Paulo, Brazil) under the number 1916-1.
.2. Puriﬁcation of sPLA2
Whole C. durissus terriﬁcus venom was ﬁrst fractioned as previ-
usly described by Toyama et al. [14]. Dried venom (45mg) was
issolved in ammonium bicarbonate buffer (1.0M; pH 8.0) and
lariﬁed by centrifugation (4500× g for 1min). The sPLA2 from C.
urissus terriﬁcus was eluted using a non-linear gradient of ace-
onitrile 66% in 0.1% of triﬂuoroacetic acid (TFA) by reverse-phase
hromatographyusing a Supelco C5 column (0.10 cm×25 cm)with
ow rate of 1mL/min with absorbance monitoring at 280nm. The
esulting PLA2 was termed sPLA2 and its purity was evaluated by
DS-PAGE.
.3. Incubation of sPLA2 with quercetin and puriﬁcation of
odiﬁed sPLA2
The incubation of sPLA2 with quercetin (mol:mol) was accord-
ng to the procedure described by Zhao et al. [15]. Quercetin
as dissolved in dimethyl sulfoxide (DMSO), and its concentra-
ion never exceeded 1% during incubation. Quercetin (400L of a
.1mM solution) was added to 400L of a homogenized, puriﬁed
PLA2 solution (1mg/mL). The mixture was incubated for 90min
t room temperature, and 200-L samples of this mixture were
oaded onto a preparative reverse-phase column to separate the
reated enzyme (sPLA2:Q) from quercetin. After column equilibra-
ion with HPLC buffer A (aqueous 0.1% TFA), samples were elutedl Interactions 189 (2011) 9–16
using a discontinuous gradient of HPLC buffer B (66.6% of ace-
tonitrile in 0.1% TFA) at a constant ﬂow rate of 1.0mL/min. The
chromatographic run was monitored at 280nm.
2.4. Electrophoresis
Electrophoresis was carried out following the Laemmli method
[16]. The degree of purity of fractions was assessed by discontinu-
ous electrophoresis using a ﬁnal acrylamide concentration of 12.5%
in the resolving gels (1.0M Tris–HCl, pH 8.8) and 5% in the stacking
gel (0.5M Tris–HCl, pH 6.8). Electrophoretic separation was carried
out in a 250 Mighty Small (Hoefer Scientiﬁc Instruments) for SDS-
PAGE. All samples and themolecularmarkerwere treatedwith SDS
and 1.0Mdithiothreitol (DTT), and the runwas conducted at 60mA
for stacking gel and 90mA for running gel. After electrophoresis,
samples were stained with Coomassie brilliant blue R-250.
2.5. Circular dichroism spectroscopy
sPLA2and sPLA2:Q (sPLA2+quercetin)weredissolved in10mM
sodium phosphate buffer (pH 7.4) and ﬁnal protein concentrations
were adjusted to 8.7mM. After centrifugation at 4000× g for 5min,
samples were transferred to a 1-mm path length quartz cuvette.
Circular dichroism spectra in the wavelength range 185–300nm
were acquired in-house with a J720 spectropolarimeter (Jasco
Corp., Japan) using a bandwidth of 1nm and a response time of
1 s. Data collection was performed at room temperature, with a
scanning speed of 100nm/min. Nine scans were obtained for each
sample, and all spectrawere corrected by subtracting buffer blanks.
2.6. Intrinsic ﬂuorescence.
The relative intrinsic ﬂuorescence intensities of sPLA2 and
sPLA2:Q were monitored with a Varian Cary Eclipse. The proteins
were solubilized inwater at room temperature. Themeasurements
were performed in a 1.5-mL 1-cm path length quartz cuvette. Flu-
orescence was measured between 300 and 450nm after excitation
at 280nm.
2.7. Mass spectrometry
The molecular mass of sPLA2 and sPLA2:Q were determined by
matrix-assisted laser desorption ionization-time-of-ﬂight (MALDI-
TOF) mass spectrometry using a Voyager-DE PRO MALDI-TOF mass
spectrometer (Applied Biosystems). One microliter of samples
(sPLA2 and sPLA2:Q) in 0.1% TFA was mixed with 2L of the matrix
-cyano-4-hydroxycinnamic acid, 50% acetonitrile, and 0.1% TFA
(v/v). The matrix was prepared with 30% acetonitrile and 0.1% TFA
(v/v). Ion masses were determined with an acceleration voltage of
25kV, the laser operated at 2890J/com2, a 300-ns delay, and the
linear analysis mode.
2.8. Measurement of sPLA2 activity
sPLA2 activity was measured following the protocol described
by Lee et al. [17] and modiﬁed by Toyama et al. [14] in 96-
well plates, using 4-nitro-3-octanoyloxy-benzoic acid (4N3OBA,
BIOMOL, USA) as substrate. Enzyme activity, expressed as the ini-
tial velocity of the reaction (Vo), was calculated based on the
increase in absorbance after 20min. All assays were performed
with absorbance at 425nmusing a SpectraMax 340multiwell plate
reader (Molecular Devices, Sunnyvale, CA). After the addition of
native or treated sPLA2 (20g), the reactionmixturewas incubated
for up to 40min at 37 ◦C and the absorbance read at 5-min intervals.
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sPLA2 was isolated from C. durissus terriﬁcus venom through
reverse-phase chromatography (Fig. 1a) and its enzymatic activity
was evaluatedusing4-nitro-3-octanoyloxy-benzoic acid (4N3OBA)
as a substrate. SDS-PAGE revealed the presence of one protein bandC.A. Cotrim et al. / Chemico-Bio
.9. Antibacterial activity
The antibacterial activity was assayed as described by Santi-
adelha et al. [18] and the structural modiﬁcation was done
ollowing the method of Toyama et al. [19]. Clavibacter michiga-
ensis michiganensis cells were harvested from fresh agar plates
nd suspended in sterile distilled water (A600nm =3×108 CFU/mL).
liquots of bacterial suspension were diluted to 103 colony-
orming units/mL (CFU/mL) and incubated with sPLA2 or sPLA2:Q
amples (75g/mL) for 60min at 28 ◦C. Survival was assayed on
utrient agar (Difco) plates (n=5). For both antibacterial assays,
lectron microscopy assessments of morphologic alterations were
erformed in the presence of saline (negative control), quercetin
100M, quercetin control), sPLA2, and sPLA2:Q.
.10. Paw edema assay
Paw edema assays were performed with the aim of evaluate
he inﬂammatory activity induced by sPLA2. For this assay female
wissmicewere used, since they show a lower aggressive behavior
han male mice. Paw edema was induced by a single subplan-
ar injection of 25L sPLA2 or sPLA2:Q (25g/paw). Paw volume
as measured immediately before the injection and at selected
ime intervals thereafter (30, 60, 120, 180, and 360min) using a
ydroplethysmometer (model 7150, Ugo Basile, Italy). All sam-
les were dissolved in sterile saline solution (0.9%). Results were
xpressed as the increase in paw volume (L) and calculated by
ubtracting the basal volume from the volume following treatment.
.11. Neurotoxic effect assay
Male chicks (4–8 days old) were killed with ether, and the
iventer cervicis muscle was removed [20] and mounted under a
esting tension of 1 g in a 4mL organ bath containing aerated (95%
2 +5% CO2) Krebs solution (118.7mM NaCl, 4.7mM KCl, 1.88mM
aCl2, 1.17mM KH2PO4, 1.17mM MgSO4, 25.0mM NaHCO2 and
1.65mM glucose, pH 7.5) at 37 ◦C. A bipolar platinum ring elec-
rode was placed around the tendon, which ran the length of
he nerve trunk supplying the muscle. Indirect stimulation was
pplied with a Grass S4 stimulator (0.1Hz, 0.2ms, 3–4mV). Mus-
le contractions and contractures were recorded by connecting the
reparation to a force displacement transducer (Narco Biosystems
nc.) coupled to a Gould RS 3400 recorder. Contractures to exoge-
ous acetylcholine (ACh, 55 or 110M for 60 s) and KCl (5mM for
20–130 s) were obtained in the absence of nerve stimulation prior
o the addition of sPLA2or sPLA2:Q (10g/mL) and at the endof the
xperiment. The preparations were allowed to stabilize for at least
0min before the addition of Ach, KCl, or a single concentration
10g/mL) of the compounds.
.12. Platelet aggregation studies
Platelet aggregation activities were assayed as described by
oyama et al. [19]. Brieﬂy, venous blood was collected with
nformed consent from healthy volunteers who denied taking any
edication in the previous 14 days. Collected blood was immedi-
tely transferred into polypropylene tubes containing one-tenth
f ﬁnal volume of acid citrate dextrose (ACD-C; citric acid 3%,
risodium citrate 4%, glucose 2%; 1:9 v/v). Platelet-rich plasma
PRP) was obtained by centrifuging whole blood at 200× g for
5min. PRP was washed in a wash buffer solution (NaCl 140mM,
Cl 5mM, sodium citrate 12mM, glucose 10mM and saccharose
2mM;pH6; 5:7 v/v) and centrifuged at 800× g for 12min at 20 ◦C.
he platelet pellet was gently resuspended in Krebs–Ringer solu-
ion and counts were performed on a Neubauer chamber. The ﬁnal
latelet suspension was adjusted to 1.2×108 platelets/mL. Plateletl Interactions 189 (2011) 9–16 11
aggregation was carried out using 400L of the washed platelet
solution in a cuvette and incubated at 37 ◦C with constant stirring.
The desired concentration of protein was added 3min prior to the
addition of a platelet aggregation inducer (thrombin). Aggregation
was subsequently recorded for 5–10min with an aggregometer
(Chrono-log Lumi-Aggregometer model 560-Ca, Havertown, PA,
USA). Aggregation experiments were performed with a concentra-
tion of 15g/mL of sPLA2 and sPLA2:Q.
2.13. Myotoxic activity
The liberation of creatine kinase (CK) from damaged muscle
cells was followed by use of the CK-NAc kit (Laborlab) to mea-
sure the enzyme activity in mice plasma. Five groups of animals
(18–22g) were injected in the right gastrocnemius muscle with
25L of 1.0mg/mL of sPLA2, sPLA2:Q, or quercetin (n=4) while
the control group received an equal volume of 0.15M NaCl. Blood
was collected from the tail after 1h into tubes containing heparin.
The amount of CK was determined using 4L plasma, which was
incubated for 3min at 37 ◦C with 1.0mL of the reagent according
to the kit protocol. Activity was expressed in units per liter (U/L).
2.14. Molecular modeling (docking)
The structural optimization of the quercetin ligand was initially
achieved using the quantum chemical AM1 method [21] imple-
mented in the BioMedCache program (BioMedCache, 1989) with
default values for the convergence criteria. Docking calculations
were performed with the GOLD 4.0 program [22] to obtain the in
silico afﬁnity of quercetin to the Crotoxin B target, a basic sPLA2
from C. durissus terriﬁcus venom. This sPLA2 structure was taken
from the RCSB Protein Data Bank [PDB] under the PDB code 2QOG.
The structure of the B chain was chosen for calculations, maintain-
ing the Ca2+ ion and thewatermolecule number 188, located 3.16 A˚
from Ca2+.
Docking calculations were performed to consider the ﬂexibility
of the quercetin ligand in such a way that torsions were consid-
ered active during the calculation. The active site was deﬁned as
all atoms within a 10-A˚ radius from His48, an important residue
according to the literature [23,24].
2.15. Statistical analyses
Resultswere reported asmeans± SEMof replicate experiments.
The signiﬁcance of differences between means was assessed by
an analysis of variance, followed by a Dunnett’s test when sev-
eral experimental groups were compared to the control group. The
conﬁdence limit for signiﬁcance was 5%.
3. Results
3.1. Puriﬁcation of sPLA2 and Incubation of sPLA2 with quercetinwith a molecular mass of 14kDa (Fig. 1c), corresponding to sPLA2.
After incubation with quercetin, sPLA2:Q (sPLA2+quercetin)
eluted at 23.7min whereas sPLA2 had a retention time of 24.3min
(Fig. 1b). This difference indicates an interaction between sPLA2
and quercetin, which changed the hydrophobicity of sPLA2.
12 C.A. Cotrim et al. / Chemico-Biologica
Fig. 1. Puriﬁcation and chemical modiﬁcation of secretory phospholipase A2
(sPLA2). (a) Fractionation of whole venom was performed by reverse-phase HPLC
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using C. michiganensis michiganensis (Gram-positive). As shown in
Fig. 4b, sPLA2 has a higher inhibitory potential on bacterial growth
than sPLA2:Q, since sPLA2 decreased CFU levels to 9.8% (90.2% inhi-
bition) compared to 63.5% (only 36.5% inhibition) for sPLA2:Q.C5 column 0.10 cm×25 cm) using a non-linear concentration gradient of buffer to
btain a high purity protein. (b) Reverse phaseHPLC proﬁle of sPLA2 before and after
odiﬁcation with quercetin. (c) Tricine SDS-PAGE of sPLA2 from Crotalus durissus
erriﬁcus.
.2. Circular dichroism spectroscopy
The effect of quercetin on the sPLA2 structure was evaluated
y absorption spectra of sPLA2 and sPLA2:Q, circular dichroism,
nd ﬂuorescence spectroscopy. As shown in Fig. 2a, few modi-
cations were observed in the 270–280nm wavelength region.
owever, some changes were observed on CD and ﬂuorescence
pectra after treatmentwith quercetin. CD spectra analysis showed
odiﬁcations mainly in the region corresponding to the -helices,
uggesting that quercetin is able to induce changes in the secondary
tructure of this enzyme (Fig. 2b).
.3. Intrinsic ﬂuorescence
The presence of aromatic amino acids such as tryptophan and
yrosine in the protein chain allows the use of ﬂuorescence spectra,
hich is sensitive for the investigation of protein conformation and
igand binding. Fig. 3a shows an increase in the intensity of ﬂuores-
ence emission spectra after treatment with quercetin, suggesting
hat this ﬂavonoid is able to change the structure of the protein
t the tertiary structure level, however, ﬂuorescence spectrum of
uercetin has shown that this compound has a peak of ﬂuores-
ence near the region of the tryptophan and possibly contributes
o increase the ﬂuorescence observed..4. Mass spectrometry
Mass spectrometry by MALDI-TOF indicated that the exact
olecular mass of the native protein is 14,425.56Da while thatl Interactions 189 (2011) 9–16
of sPLA2:Q is 14,727.79 (Fig. 3b), an increase of 302.23Da in sPLA2
treated with quercetin, suggesting that one molecule of quercetin
is bound to the protein structure.
3.5. Measurement of sPLA2 activity and antibacterial activity
The effect of quercetin on sPLA2 enzymatic activity was evalu-
ated. Both enzymes, sPLA2 and sPLA2:Q exhibit allosteric behavior
(Fig. 4a), and quercetin strongly inhibits sPLA2 activity. The max-
imum velocity after 20min for sPLA2 was 0.330±0.04vo/mol
whereas for sPLA2:Q was 0.196±0.02vo/mol, showing a signif-
icant decrease of 40%. To analyze possible correlations between
the enzymatic activity of sPLA2 and its antibacterial activity, bacte-
rial viability was tested by CFU counting. The assay was performedFig. 2. UV/vis absorption and circular dichroism (CD) spectra. (a) Absorption spec-
trum of sPLA2 and sPLA2 after treatment with quercetin (sPLA2:Q) at wavelength
intervals 200–300nm. The proteins were analyzed at 280nm. (b) CD spectra of
native sPLA2 and sPLA2:Q. Data over the range 185–280nm are shown. The CD
spectra are expressed in theta machine units in millidegrees.
C.A. Cotrim et al. / Chemico-Biologica
Fig. 3. Intrinsic ﬂuorescence and mass spectrometry. (a) Intrinsic ﬂuorescence of
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4. Discussion and conclusions
In this study, sPLA2 from C. durissus terriﬁcus was modiﬁed
by quercetin, a ﬂavonoid known for its anti-inﬂammatory activ-ative sPLA2 and sPLA2:Q was measured with excitation at 280nm and emission
onitoring between 300 and 450nm. (b) MALDI-TOF mass spectrometry analysis
f native sPLA2 and sPLA2:Q shows a difference between the molecular masses
orresponding to one molecule of bound quercetin.
.6. Paw edema assay
Since ﬂavonoids have shown a good capacity to inhibit sPLA2
nd consequently decrease its pro-inﬂammatory activity [13,25],
he effect of quercetin on sPLA2 was evaluated. Following subplan-
ar injections on Swiss mice, sPLA2 had a huge potential to induce
dema after 60min (Fig. 5a). Under the same experimental con-
itions, sPLA2:Q did not show a decrease in edema effect, but the
aximum edema was observed after 30min.
.7. Neurotoxic effect assay
When the neurotoxic activity was evaluated, both sPLA2 and
PLA2:Q induced neuromuscular blockage, but sPLA2 induced a
aster effect at 80min, whereas sPLA2:Q had a similar behavior at
00min (Fig. 5b), suggesting that quercetin changed the velocity of
ative sPLA2 binding to the neurotoxic site of chick biventer mus-
le. However, this change is not able to abolish the neurotoxic effect
f sPLA2.
.8. Platelet aggregation studiesIn order to evaluate the anti-coagulant potential induced by
PLA2wereperformedplatelet aggregation assays. The results have
hown that sPLA2 from C. durissus terriﬁcus has a moderate abil-
ty to cause aggregation of washed platelets. While sPLA2 from
. durissus cascavella induces about 85% aggregation at 3g/Ll Interactions 189 (2011) 9–16 13
[26], sPLA2 from C. durissus terriﬁcus induced 70% aggregation at
a concentration of 20g/L. Treatment with quercetin decrease
this effect, with 32% aggregation induced by sPLA2:Q at the same
concentration (Fig. 5c).
3.9. Myotoxic activity
The ability of sPLA2 to cause myonecrosis was also evaluated
through measurement of released creatine kinase. Fig. 5d shows
that sPLA2 induces an increase in plasma creatine kinase levels
of 821.39±107.8U/L, indicating its ability to cause muscle dam-
age. Treatment with quercetin signiﬁcantly decreased the creatine
kinase levels measured to 492.28±71.5U/L, a 40% decrease.
3.10. Molecular modeling (docking)
In order to analyze possible intermolecular interactions
between sPLA2 and quercetin, we performed in silico studies using
molecular modeling (docking). The best docking solution for the
quercetin ligand is shown in Fig. 6a. The GOLD score for this result
was 43.94, showing good afﬁnity for the target. The presence of
several important intermolecular interactions such as (i) hydrogen
bonds with residues Cys45 and His48 at 2.69 and 3.00 A˚, respec-
tively; (ii) hydrogen bond with water molecule 188 at 3.16 A˚; (iii)
one polar contact with Ca2+ ion at 3.19 A˚; and (iv) hydrophobic
interactions with residue Phe5 can account for the stability of the
quercetin–sPLA2 complex (Fig. 6a and b).Fig. 4. Enzymatic andantibacterial assays. (a) Enzymatic activitywasanalyzedusing
4N3OBA as substrate and monitored at wavelength 425nm. sPLA2:Q shows a sig-
niﬁcant decrease compared to native sPLA2. (b) Effect of native sPLA2 and sPLA2:Q
against Gram-positive bacteria. Quercetin decreases the ability of sPLA2 to inhibit
Gram-positive bacteria. Error bars indicate SEM *P<0.05 compared to saline control.
14 C.A. Cotrim et al. / Chemico-Biologica
Fig. 5. Pharmacological assays. (a) Paw edema induced after the injection of sPLA2
and sPLA2:Q (25g/paw) into the right paw of Swiss mice. Measurements were
done after 30, 60, 120, 180 and 240min, with no differences observed after treat-
ment with quercetin. (b) Neurotoxic effect of sPLA2 and sPLA2:Q on chick biventer
cervicis muscle. Results were expressed as the percentage change in twitch tension.
(c) Percent platelet aggregation caused by native sPLA2 and sPLA2:Q. The washed
platelets assay was performed with venous blood collected from healthy volun-
teers and the concentration of both proteins was 15g/mL (d) Myonecrosis was
assayed based on the creatine kinase levels in Swiss mice. Twenty-ﬁve micrograms
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results have showed that some pharmacological activities such as
inﬂammatory and neurotoxicitywere not inhibited after treatment
with quercetin. This result corroborates the proposal by Ohno et al.
[32],who suggested the existence of a distinct pharmacological sitef native sPLA2, sPLA2:Q, and pure quercetin were injected into the gastrocnemius
uscle. Results were expressed as units of enzymatic activity per liter (U/L). Error
ars indicate the SEM. *P<0.05 compared to sPLA2 activity.
ties. Treatment with quercetin resulted in modiﬁcation of the
rotein secondary structure as observed in circular dichroism
ssay (Fig. 2b). Similar results were observed by Iglesias et al.
12] with sPLA2 from C. durissus cascavella after modiﬁcation with
he ﬂavonoid morin. Although a secondary structure modiﬁcation
ould be observed, the results do not allow concluding about ter-
iary structure modiﬁcation, once the ﬂuorescence spectrum of
uercetin has shown that this compound has a ﬂuorescent peak
ear the region of the tryptophan, suggesting that the increase in
he total ﬂuorescence of the protein might be caused due to the
onding of quercetin.
Treatmentwithquercetin led toadecreaseof about40% in sPLA2
nzymatic activity, similar to p-bromophenacyl bromide (p-BPB),
PLA2 inhibitor. Docking studies suggest that quercetin binds inl Interactions 189 (2011) 9–16
the vicinity of the His48 residue, leading to inhibition of enzymatic
activity. As shown by Verheij et al. [23], and Scott and Sigler [24],
these amino acids are fundamental to enzymatic activity; His48 is
involved in the ﬁrst step of the enzymatic mechanism, and Asp49
is important for binding to Ca2+, a cofactor. It seems that quercetin
bound to sPLA2 interfereswith thebindingbetween theproteinand
its substrate. Soares et al. [27] suggested that enzymatic activity is
not required for antibacterial activity after chemical modiﬁcation
with BPB and EDTA in a C. durissus terriﬁcus sPLA2 isoform, and
the same was observed by Diz Filho et al. [28] for Crotalus durissus
ruruima. However, our results show correlation between the enzy-
matic and antibacterial activities against Gram-positive bacteria.
Treatment of sPLA2 with quercetin decreased both these activities.
According to Buckland and Wilton [29], mammalian PLA2 phos-
pholipid hydrolysis is correlatedwith antibacterial activity because
both are calcium dependent. We believe this isoform behaves as a
mammalian PLA2 in this respect.
Several studies have investigated the anti-inﬂammatory effects
of ﬂavonoids as well as their effect on both catalytic and phar-
macological activities of PLA2 [8,11,12,30,31]. According to these
models, quercetin molecules would interact with the enzymatic
site thus affecting enzymatic and pharmacological activities. OurFig. 6. Molecular docking. (a) Best docking solution for quercetin (stick model) and
important interacting residues of the Crotoxin B target, besides Ca2+ ion and water
oxygen. (b) Detailed view, with hydrogen bonds (distances in A˚) shown as lines not
involving the Ca2+ ion. Hydrogen atoms were omitted for clarity and the lines linked
to the Ca2+ ion represent the coordination polyhedron.
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ear the C-terminal region of PLA2 away from the catalytic site.
fter modiﬁcations with 7-hydroxycoumarin, Toyama et al. [31]
bserved thatdecreasing theenzymatic activityhadnot suppressed
he pharmacological effect of PLA2, suggesting the presence of a
istinct site. Although the inﬂammatory and neurotoxic effects
ere unchanged after treatment with quercetin, the myotoxic and
latelet aggregationeffectsweredecreasedby40%and55%, respec-
ively, indicatingdependencyon the enzymatic activity.Webelieve
hat perhaps both the myotoxic and the platelet aggregation sites
re located in a second pharmacological site near the calcium bind-
ng loop as proposed by Valentin and Lambeau [33]. Thus, after
inding to the protein near that region, quercetin affects this site
ore directly leading to considerable changes in these activities.
Molecular docking has been used during the last decades due to
ts importance in elucidating, through computational approaches,
he best matches for protein–ligand interactions [34]. In this study,
olecular docking was an important tool in evaluating the inter-
ctions between sPLA2 and quercetin. Our result agrees with that
bserved by mass spectrometry, showing that one molecule of
uercetin is binding to the protein. Additionally, molecular dock-
ng was useful in elucidating some important interactions between
PLA2 and quercetin, which allowed better understanding of the
olecular reasons for the effects of quercetin aswell as other struc-
urally similar ﬂavonoids that could be studied in the future.
The results shownhere ledus to conclude that quercetin binding
o theproteindecreased the catalytic activity of sPLA2 fromC. duris-
us terriﬁcus. This sPLA2 probably has two distinct pharmacological
ites: one responsible for effects such as platelet aggregation,
yotoxicity, and antibacterial activities; and another responsible
or inﬂammatory and neurotoxic effects. We believe the ﬁrst one
s located near the calcium-binding loop region and consequently
ear the catalytic site where quercetin binds to the protein, thus
eading to a loss of activities dependent on this site. The second
ne,we believe is located near C-terminal region, away fromwhere
uercetin binds, and is not directly or indirectly affected by the
uercetin binding to the catalytic site. Other ﬂavonoids with very
imilar chemical structures have a potential to interact with sPLA2
rom serpents. Further docking studies with new molecules of this
lass could be useful in predicting how potent these compounds
ould be as sPLA2 inhibitors. Although our study clariﬁes some
spects of the chemical and pharmacological interactions between
ﬂavonoid and a sPLA2, further studies are necessary to better
nderstand the action of ﬂavonoids on sPLA2 activities.
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